Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s What Happened
by Jessica Moore · The Cerbat GemShionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $10.19, but opened at $9.7899. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.75, with a volume of 6,315 shares trading hands.
Wall Street Analysts Forecast Growth
SGIOY has been the topic of a number of research reports. Zacks Research downgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 16th. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.
Get Our Latest Analysis on SGIOY
Shionogi & Co., Ltd. Unsponsored ADR Stock Performance
The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $11.01 and a 200 day moving average price of $9.61. The stock has a market cap of $16.52 billion, a PE ratio of 12.78, a P/E/G ratio of 0.75 and a beta of 0.19.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last posted its quarterly earnings data on Friday, January 30th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.09. The business had revenue of $966.53 million for the quarter, compared to analysts’ expectations of $848.42 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.70% and a net margin of 41.82%. Analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.73 earnings per share for the current year.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.